Form 4: Perceptive Advisors and Joseph Edelman Report Beneficial Ownership Changes in Nautilus Biotechnology

Perceptive Advisors LLC, Perceptive Life Sciences Master Fund Ltd., and Joseph Edelman report changes in beneficial ownership of Nautilus Biotechnology, Inc. stock due to option grants.

Summary

• Perceptive Advisors LLC, Perceptive Life Sciences Master Fund Ltd., and Joseph Edelman filed a Form 4 detailing changes in their beneficial ownership of Nautilus Biotechnology, Inc. (NAUT) securities.
• The report indicates that Michael Altman, affiliated with Perceptive Advisors LLC, received stock options for 45,000 shares of NAUT common stock on June 14, 2024, at an exercise price of $2.56.
• These options vest monthly over a 12-month period, contingent upon Mr. Altman's continuous service as a 'Service Provider' as defined in the Issuer's 2021 Equity Incentive Plan.
• Perceptive Advisors LLC may have an indirect pecuniary interest in these options due to a management fee offset arrangement related to Mr. Altman's board service.
• Joseph Edelman, as the managing member of Perceptive Advisors LLC, which serves as the investment manager of Perceptive Life Sciences Master Fund Ltd., disclaims beneficial ownership of the reported securities except to the extent of his/its indirect pecuniary interest.

Sentiment

Score: 6

Explanation: The document is a standard regulatory filing, indicating routine activity. The sentiment is neutral, with a slight positive leaning due to the incentive alignment of stock options.

Positives

• The granting of stock options to a board member aligns interests with shareholders.
• The vesting schedule incentivizes continued service and contribution from the board member.

Risks

• The vesting of the options is contingent upon Mr. Altman's continuous service, creating a potential risk if he ceases to be a 'Service Provider'.
• The indirect pecuniary interest of Perceptive Advisors LLC could potentially influence decisions.

Management Comments

• Joseph Edelman disclaims beneficial ownership of the securities reported on this form, except to the extent of his/its indirect pecuniary interest therein.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Comparison to Industry Standards

• Stock option grants to board members are a common practice in the biotechnology industry to align their interests with the long-term success of the company.
• Vesting schedules are typically structured to incentivize continued service and contribution, often over a period of several years.
• Disclosure of indirect pecuniary interests is a standard requirement to ensure transparency and avoid potential conflicts of interest.

Stakeholder Impact

• The granting of stock options to a board member can positively impact shareholders by aligning interests and incentivizing long-term value creation.

Key Dates